Astellas Buys Global Rights To Develop, Market Aska Prostate Drug
This article was originally published in PharmAsia News
Executive Summary
Japan's Aska Pharmaceutical and Astellas Pharma have reached a licensing agreement covering a drug to treat benign prostate hyperplasia